--- title: "Scinai Immunotherapeutics (SCNI) news: offering" url: "https://aibio.space/companies/scinai-immunotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SCNI offering news: Scinai Immunotherapeutics raises $1.38 million through Yorkville equity line drawdowns. Scinai Immunotherapeutics Ltd." --- SCNI Scinai Immunotherapeutics Ltd. NASDAQ · Israel # Scinai Immunotherapeutics (SCNI) news SCNI offering news Listings · 2026-09-21 ## [Scinai Immunotherapeutics regains Nasdaq bid price compliance](https://aibio.space/news/scinai-immunotherapeutics-regains-nasdaq-bid-price-compliance/) Nasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed. ## Latest Scinai Immunotherapeutics news 1. 2025-06-12 Financings [Scinai Immunotherapeutics raises $1.38 million through Yorkville equity line drawdowns](https://aibio.space/news/scinai-immunotherapeutics-raises-1-38-million-through-yorkville-equity/) The sales were priced at about $3.03 per ADS, a 3% discount to market. Scinai also says a cost-cutting program will lower annual employment costs by about $815,000. 2. 2025-04-29 Distress [Scinai files late 20-F notice over accounting for $29 million loan conversion](https://aibio.space/news/scinai-files-late-20-f-notice-accounting-29-million-loan-conversion/) The company cites the conversion of its European Investment Bank debt to preferred equity and personnel losses after year-end, and expects to file by May 15, 2025. ## Scinai Immunotherapeutics at a glance - **Ticker**: SCNI - **Listing**: NASDAQ - **Country**: Israel - **Cash, Dec 31, 2025**: $1.7 million ### Related companies - [Rafa Laboratories](https://aibio.space/companies/rafa-laboratories/) TASE: RAFA - [NEXTAGE Therapeutics](https://aibio.space/companies/nextage-therapeutics/) TASE: NXTG - [RAPHAEL PHARMACEUTICAL INC.](https://aibio.space/companies/raphael-pharmaceutical/) OTC: RAPH - [Compugen](https://aibio.space/companies/compugen/) NASDAQ: CGEN - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) TASE: EPIT - [SciSparc](https://aibio.space/companies/scisparc/) NASDAQ: SPRC - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) AMEX: RGNT ### Also on NASDAQ - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) CNSP - [Alphatec Holdings](https://aibio.space/companies/alphatec/) ATEC - [ILLUMINA, INC.](https://aibio.space/companies/illumina/) ILMN - [BridgeBio Oncology Therapeutics](https://aibio.space/companies/bridgebio-oncology-therapeutics/) BBOT - [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) VIR - [Shattuck Labs](https://aibio.space/companies/shattuck-labs/) STTK ## Scinai Immunotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | [$658,000](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | | Research and development | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | [$5.5 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | | Net income (loss) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | | Cash from operations | [-$6.0 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | [-$6.3 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | | Cash and equivalents | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Scinai Immunotherapeutics Has Scinai Immunotherapeutics raised money recently? Our latest story on this, dated Jun 12, 2025: "Scinai Immunotherapeutics raises $1.38 million through Yorkville equity line drawdowns". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scinai-immunotherapeutics-raises-1-38-million-through-yorkville-equity/). What is the ticker symbol of Scinai Immunotherapeutics? Scinai Immunotherapeutics Ltd. trades under the ticker SCNI on NASDAQ. Where is Scinai Immunotherapeutics listed? Scinai Immunotherapeutics Ltd. is listed on NASDAQ. What is the SEC CIK of Scinai Immunotherapeutics? The SEC Central Index Key (CIK) for Scinai Immunotherapeutics Ltd. is 1611747. Its filings are on SEC EDGAR. How many shares does Scinai Immunotherapeutics have outstanding? 13,872,899,584 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-01. Which country or territory is Scinai Immunotherapeutics listed under? Our directory records Scinai Immunotherapeutics Ltd. under Israel. What does Scinai Immunotherapeutics do? Our directory classifies Scinai Immunotherapeutics Ltd. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Scinai Immunotherapeutics? The ISIN recorded for Scinai Immunotherapeutics Ltd. is US09073Q4029. Does aibio.space cover Scinai Immunotherapeutics? aibio.space lists Scinai Immunotherapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Scinai Immunotherapeutics incorporated? SEC records list its state or country of incorporation as L3. What was Scinai Immunotherapeutics's revenue last year? $1.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Scinai Immunotherapeutics profitable? Scinai Immunotherapeutics Ltd. reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2025, and used $6.0 million of cash in operations, per its annual report to the SEC. How much does Scinai Immunotherapeutics spend on research and development? $2.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Scinai Immunotherapeutics have? $1.7 million in cash at Dec 31, 2025, per its 20-F. What is the latest Scinai Immunotherapeutics (SCNI) stock news? Our latest story on Scinai Immunotherapeutics, dated Sep 21, 2026: "Scinai Immunotherapeutics regains Nasdaq bid price compliance". Nasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed. [Source](https://aibio.space/news/scinai-immunotherapeutics-regains-nasdaq-bid-price-compliance/). ## Investor discussion: Scinai Immunotherapeutics Members talk about Scinai Immunotherapeutics (SCNI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Scinai Immunotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390026101636/ea030605801ex99-1.htm) 2. 2026-08-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390026091445/ea0302675-6k_scinai.htm) 3. 2026-05-08 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390026053561/ea028869301ex99-1.htm) 4. 2026-03-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390026031611/ea028260401ex99-1.htm) 5. 2025-06-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390025053720/ea024555401ex99-1_scinai.htm) 6. 2025-04-29 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390025036856/ea024003501-nt20f_scinai.htm) 7. 2025-03-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390025020786/ea023322701ex99-1_scinai.htm) 8. 2024-11-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611747/000121390024101860/ea022225101ex99-1_scinai.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SCNI on TradingView](https://www.tradingview.com/symbols/NASDAQ-SCNI/). ## SEC filings and registration - **SEC name**: Scinai Immunotherapeutics Ltd. - **CIK**: 1611747 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SCNI (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, Israel, 00000 - **Phone**: 972-8-9302529 - **Shares outstanding**: 13,872,899,584 as of 2025-12-31 (20-F filed 2026-04-01) - **Former names**: BiondVax Pharmaceuticals Ltd. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026110869/ea0309143-6k_scinai.htm) filed 2026-10-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026110069/ea0308852-6k_scinai.htm) filed 2026-10-16 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026109633/ea0308605-6k_scinai.htm) filed 2026-10-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026108730/ea0308438-6k_scinai.htm) filed 2026-10-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026101636/ea0306058-6k_scinai.htm) filed 2026-09-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026097891/ea0304833-6k_scinai.htm) filed 2026-09-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026093738/ea0302364-6k_scinai.htm) filed 2026-08-26 - [6-K](https://www.sec.gov/Archives/edgar/data/1611747/000121390026091445/ea0302675-6k_scinai.htm) filed 2026-08-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611747), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Scinai Immunotherapeutics Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SCNI, recorded under Israel. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Scinai Immunotherapeutics Ltd. - **Ticker**: SCNI - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US09073Q4029 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SCNI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/scinai-immunotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Scinai Immunotherapeutics (SCNI) news: offering", 2026-10-31, https://aibio.space/companies/scinai-immunotherapeutics/